Found: 812
Select item for more details and to access through your institution.
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 4, p. 541, doi. 10.1007/s40257-024-00858-z
- By:
- Publication type:
- Article
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 7, p. 1, doi. 10.1007/s00262-024-03697-3
- By:
- Publication type:
- Article
Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 4, p. 819, doi. 10.1007/s10120-024-01500-x
- By:
- Publication type:
- Article
Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 4, p. 840, doi. 10.1007/s10120-024-01509-2
- By:
- Publication type:
- Article
Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 7, p. 932, doi. 10.1007/s10147-024-02515-1
- By:
- Publication type:
- Article
The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 7, p. 1019, doi. 10.1007/s10147-024-02538-8
- By:
- Publication type:
- Article
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.
- Published in:
- Yonsei Medical Journal, 2024, v. 65, n. 7, p. 371, doi. 10.3349/ymj.2023.0263
- By:
- Publication type:
- Article
Case report: Ipilimumab and nivolumab in metastatic adrenocortical cancer with high tumor mutational burden.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1406616
- By:
- Publication type:
- Article
Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Cancers, 2024, v. 16, n. 12, p. 2196, doi. 10.3390/cancers16122196
- By:
- Publication type:
- Article
Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials.
- Published in:
- Cancers, 2024, v. 16, n. 12, p. 2223, doi. 10.3390/cancers16122223
- By:
- Publication type:
- Article
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study.
- Published in:
- Cancers, 2024, v. 16, n. 12, p. 2251, doi. 10.3390/cancers16122251
- By:
- Publication type:
- Article
Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC.
- Published in:
- Cancers, 2024, v. 16, n. 12, p. 2287, doi. 10.3390/cancers16122287
- By:
- Publication type:
- Article
Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12479-0
- By:
- Publication type:
- Article
Successful R0 resection after chemotherapy, including nivolumab, for gastric cancer with liver metastases: three case reports.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer.
- Published in:
- Journal of Gynecologic Oncology, 2024, v. 35, p. 24, doi. 10.3802/jgo.2024.35.S2.P7
- By:
- Publication type:
- Article
Esophageal chemoradiotherapy with concurrent nivolumab: Pilot results in the palliative treatment of oligometastatic disease.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2024, v. 20, n. 3, p. 416, doi. 10.1111/ajco.14057
- By:
- Publication type:
- Article
Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment—The Experience of Ion Chiricuță Oncology Institute.
- Published in:
- Cancers, 2024, v. 16, n. 11, p. 2022, doi. 10.3390/cancers16112022
- By:
- Publication type:
- Article
Enhancing Effector Jurkat Cell Activity and Increasing Cytotoxicity against A549 Cells Using Nivolumab as an Anti-PD-1 Agent Loaded on Gelatin Nanoparticles.
- Published in:
- Gels (2310-2861), 2024, v. 10, n. 6, p. 352, doi. 10.3390/gels10060352
- By:
- Publication type:
- Article
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs: approval of nivolumab for unresectable advanced or recurrent epithelial skin malignancies in Japan.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 6, p. 639, doi. 10.1007/s10147-024-02524-0
- By:
- Publication type:
- Article
Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study.
- Published in:
- International Journal of Clinical Pharmacy, 2024, v. 46, n. 3, p. 745, doi. 10.1007/s11096-024-01713-1
- By:
- Publication type:
- Article
Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
- Published in:
- Oncologist, 2024, v. 29, n. 6, p. 511, doi. 10.1093/oncolo/oyae003
- By:
- Publication type:
- Article
Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.
- Published in:
- Journal of Pharmaceutical Health Care & Sciences, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s40780-024-00348-8
- By:
- Publication type:
- Article
Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments.
- Published in:
- Clinical Medicine Insights: Oncology, 2024, p. 1, doi. 10.1177/11795549241257238
- By:
- Publication type:
- Article
Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-63403-2
- By:
- Publication type:
- Article
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12336-0
- By:
- Publication type:
- Article
The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab.
- Published in:
- Clinical & Experimental Medicine, 2024, v. 24, n. 1, p. 1, doi. 10.1007/s10238-024-01370-8
- By:
- Publication type:
- Article
Immune checkpoint inhibitors and pericardial disease: a systematic review.
- Published in:
- Cardio-Oncology, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s40959-024-00234-0
- By:
- Publication type:
- Article
Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status.
- Published in:
- Cancers, 2024, v. 16, n. 10, p. 1825, doi. 10.3390/cancers16101825
- By:
- Publication type:
- Article
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-46961-x
- By:
- Publication type:
- Article
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis.
- Published in:
- Journal of the Egyptian National Cancer Institute, 2024, v. 36, n. 1, p. 1, doi. 10.1186/s43046-024-00218-2
- By:
- Publication type:
- Article
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 9, p. 1, doi. 10.1002/cam4.7235
- By:
- Publication type:
- Article
High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy.
- Published in:
- Cancers, 2024, v. 16, n. 9, p. 1737, doi. 10.3390/cancers16091737
- By:
- Publication type:
- Article
Aktualisierte S3-Leitlinie Nierenzellkarzinom.
- Published in:
- Die Urologie, 2024, v. 63, n. 5, p. 439, doi. 10.1007/s00120-024-02328-0
- By:
- Publication type:
- Article
A case report of severe pulmonary arterial hypertension after nivolumab, an IgG4 anti-PD1 monoclonal antibody.
- Published in:
- European Heart Journal Case Reports, 2024, v. 8, n. 5, p. 1, doi. 10.1093/ehjcr/ytae222
- By:
- Publication type:
- Article
Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma.
- Published in:
- In Vivo, 2024, v. 38, n. 3, p. 1451, doi. 10.21873/invivo.13589
- By:
- Publication type:
- Article
Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 9, p. 2456, doi. 10.3390/jcm13092456
- By:
- Publication type:
- Article
Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).
- Published in:
- PLoS ONE, 2024, v. 19, n. 4, p. 1, doi. 10.1371/journal.pone.0299742
- By:
- Publication type:
- Article
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12153-5
- By:
- Publication type:
- Article
The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer.
- Published in:
- Alternative Therapies in Health & Medicine, 2024, v. 30, n. 4, p. 90
- By:
- Publication type:
- Article
MIMS - UPDATES: NEW INDICATIONS.
- Published in:
- Australian Journal of Pharmacy, 2024, v. 105, n. 1237, p. 29
- Publication type:
- Article
Immunotherapy and Cannabis: A Harmful Drug Interaction or Reefer Madness?
- Published in:
- Cancers, 2024, v. 16, n. 7, p. 1245, doi. 10.3390/cancers16071245
- By:
- Publication type:
- Article
Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab.
- Published in:
- Cancers, 2024, v. 16, n. 7, p. 1409, doi. 10.3390/cancers16071409
- By:
- Publication type:
- Article
Aortic rupture following acute aortitis in a patient with head and neck carcinoma treated with nivolumab: a rare but severe immune-related adverse event.
- Published in:
- European Archives of Oto-Rhino-Laryngology, 2024, v. 281, n. 4, p. 2037, doi. 10.1007/s00405-024-08495-2
- By:
- Publication type:
- Article
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan.
- Published in:
- European Journal of Health Economics, 2024, v. 25, n. 3, p. 459, doi. 10.1007/s10198-023-01602-w
- By:
- Publication type:
- Article
Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 7, p. 4009, doi. 10.3390/ijms25074009
- By:
- Publication type:
- Article
Efficacy of Nivolumab in Comparison to Chemotherapy and Gefitinib for Advanced Non Small Cell Lung Cancer (NSCLC).
- Published in:
- Journal of Bangladesh College of Physicians & Surgeons, 2024, v. 42, n. 2, p. 176, doi. 10.3329/jbcps.v42i2.72362
- By:
- Publication type:
- Article
Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta‐analysis.
- Published in:
- Journal of Cosmetic Dermatology, 2024, v. 23, n. 4, p. 1165, doi. 10.1111/jocd.16105
- By:
- Publication type:
- Article